The core driver mutations of IMT are ALK rearrangements (70%), including TPM3-ALK (common) and RANBP2-ALK (highly aggressive), and are often accompanied by TP53 mutations (40%) and ROS1/PDGFRβ/NTRK (ALK-negative) fusion mutations (12, 13). This evidence concerns the gene RANBP2 and inflammatory myofibroblastic tumor.